Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON), a pharmaceutical company specializing in rare disease treatments, announced its leadership team's participation in two upcoming investor conferences. CEO Sean Brynjelsen, CFO James Gruber, and CBO David Krempa will attend:

1. The 25th Annual B. Riley Securities Investor Conference on May 22, 2025, at 11:15am ET in Marina Del Rey, California, featuring a fireside chat

2. The 22nd Annual Craig-Hallum Institutional Investor Conference on May 28, 2025, in Minneapolis, Minnesota

One-on-one meetings can be arranged through B. Riley or Craig Hallum representatives. No webcasts will be available for either conference.

News Market Reaction

+15.07%

1 alert

+15.07% News Effect

On the day this news was published, ETON gained 15.07%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, James Gruber, Chief Financial Officer, and David Krempa, Chief Business Officer, will participate in two upcoming investor conferences as follows:

• The 25^th Annual B. Riley Securities Investor Conference
  Date: Thursday, May 22, 2025, at 11:15am ET/8:15am PT (Fireside Chat)
  Location: The Ritz-Carlton, Marina Del Rey, California

• The 22nd Annual Craig-Hallum Institutional Investor Conference
  Date: Wednesday, May 28, 2025
  Location: Depot Renaissance Hotel, Minneapolis, Minnesota

To schedule a 1x1 meeting with the Company, please contact your B. Riley or Craig Hallum institutional sales representative.

There is no webcast for these conferences.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX^®, ALKINDI SPRINKLE^®, GALZIN^®, PKU GOLIKE^®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia^®, ET-700, ET-800 and ZENEO^® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Source: Eton Pharmaceuticals.

FAQ

When is Eton Pharmaceuticals (ETON) presenting at the B. Riley Securities Investor Conference 2025?

Eton Pharmaceuticals will present at the B. Riley Securities Investor Conference on Thursday, May 22, 2025, at 11:15am ET/8:15am PT at The Ritz-Carlton, Marina Del Rey, California.

Who will represent Eton Pharmaceuticals (ETON) at the upcoming investor conferences?

Eton Pharmaceuticals will be represented by CEO Sean Brynjelsen, CFO James Gruber, and CBO David Krempa at both conferences.

Where is the Craig-Hallum Institutional Investor Conference 2025 being held?

The 22nd Annual Craig-Hallum Institutional Investor Conference will be held at the Depot Renaissance Hotel in Minneapolis, Minnesota on May 28, 2025.

How can investors schedule meetings with Eton Pharmaceuticals (ETON) at these conferences?

Investors can schedule one-on-one meetings with Eton Pharmaceuticals by contacting their B. Riley or Craig Hallum institutional sales representative.